AMANTA

Amanta Healthcare Limited

Sterile pharmaceuticals manufacturer of IV fluids and injectables

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

amanta.co.in(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹183.41
Market cap
712 Cr
Stock P/E
48.5
P/B
3.23
Dividend yield
0.1%
ROE (FY26)
6.8%
ROCE (FY26)
9.2%
Operating margin (FY26)
14.3%
Debt / equity (FY26)
1.06
OCF / EBITDA (FY26)
80.9%
OCF / EBITDA (3Y)
86.5%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Amanta Healthcare makes sterile pharmaceutical products, mainly intravenous (IV) fluids and other sterile liquid dosage forms in plastic containers, for hospitals in India and for export markets.

Company snapshot

97thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓87% of operating profit came in as cash over the last three years — profits are backed by real cash.

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricJun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales65 Cr71 Cr74 Cr77 Cr69 Cr
Operating expenses (approx.)50 Cr56 Cr59 Cr62 Cr54 Cr
EBITDA15 Cr15 Cr15 Cr15 Cr15 Cr
OPM %22.8%20.7%20.6%19.4%21.1%
Other income0.96 Cr0.07 Cr0.68 Cr2 Cr0.64 Cr
Interest6 Cr5 Cr5 Cr4 Cr6 Cr
Depreciation5 Cr5 Cr5 Cr5 Cr5 Cr
Profit before tax5 Cr2 Cr6 Cr8 Cr4 Cr
Tax %28.8%47.0%26.6%27.4%26.3%
Net profit4 Cr1 Cr5 Cr6 Cr3 Cr
EPS (₹)₹1.22₹0.35₹1.35₹1.61₹0.85

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026TTM
Sales259 Cr280 Cr275 Cr288 CrSign in free for the trailing twelve months
Operating expenses (approx.)206 Cr223 Cr215 Cr228 CrSign in free for the trailing twelve months
EBITDA53 Cr57 Cr60 Cr60 CrSign in free for the trailing twelve months
OPM %20.4%20.5%21.7%20.8%Sign in free for the trailing twelve months
Other income4 Cr1 Cr1 Cr3 CrSign in free for the trailing twelve months
Interest35 Cr34 Cr28 Cr21 CrSign in free for the trailing twelve months
Depreciation18 Cr20 Cr18 Cr19 CrSign in free for the trailing twelve months
Profit before tax3 Cr5 Cr15 Cr21 CrSign in free for the trailing twelve months
Tax %178.5%32.6%28.6%29.6%Sign in free for the trailing twelve months
Net profit-2 Cr4 Cr11 Cr15 CrSign in free for the trailing twelve months
EPS (₹)₹-0.79₹1.35₹3.71₹4.33Sign in free for the trailing twelve months
Dividend payout %———2.7%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2023Mar 2024Mar 2025Mar 2026
Equity capital27 Cr27 Cr29 Cr39 Cr
Reserves36 Cr39 Cr68 Cr181 Cr
Borrowings216 Cr205 Cr195 Cr234 Cr
Other liabilities96 Cr81 Cr90 Cr103 Cr
Total liabilities374 Cr352 Cr382 Cr558 Cr
Fixed assets (net)229 Cr223 Cr208 Cr197 Cr
CWIP——7 Cr82 Cr
Investments3 Cr4 Cr8 Cr16 Cr
Loans & advances———0.51 Cr
Inventories69 Cr59 Cr73 Cr83 Cr
Trade receivables54 Cr48 Cr50 Cr43 Cr
Cash & bank0.11 Cr2 Cr0.22 Cr81 Cr
Other assets19 Cr17 Cr37 Cr55 Cr
Total assets374 Cr352 Cr382 Cr558 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity43 Cr58 Cr47 Cr48 Cr
Cash from investing-7 Cr-10 Cr-24 Cr-94 Cr
Cash from financing-42 Cr-46 Cr-23 Cr126 Cr
Net cash flow-6 Cr1 Cr-1 Cr81 Cr
Free cash flow (OCF − Capex)36 Cr46 Cr26 Cr-32 Cr

Ratios

MetricMar 2023Mar 2024Mar 2025Mar 2026
ROCE %13.6%14.4%14.6%9.2%
ROE %-3.4%5.5%10.9%6.8%
Debtor days75636654
Inventory days249253262311
Days payable131106110135
Cash conversion cycle194210219230
OCF / EBITDA %80.7%101.0%78.1%80.9%
OCF / EBITDA % (3 years)——86.7%86.5%
Debt / equity3.433.102.021.06
Current ratio1.351.161.201.69
Net debt / EBITDA4.093.543.262.56